92 related articles for article (PubMed ID: 9657435)
1. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
Lehne G; Nordal KP; Midtvedt K; Goggin T; Brosstad F
Thromb Haemost; 1998 Jun; 79(6):1119-25. PubMed ID: 9657435
[TBL] [Abstract][Full Text] [Related]
2. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
3. Lamifiban.
Drugs R D; 1999 May; 1(5):379-82. PubMed ID: 10566069
[No Abstract] [Full Text] [Related]
4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
[TBL] [Abstract][Full Text] [Related]
6. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study.
Théroux P; Kouz S; Roy L; Knudtson ML; Diodati JG; Marquis JF; Nasmith J; Fung AY; Boudreault JR; Delage F; Dupuis R; Kells C; Bokslag M; Steiner B; Rapold HJ
Circulation; 1996 Sep; 94(5):899-905. PubMed ID: 8790023
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
8. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
9. Lamifiban.
Dooley M; Goa KL
Drugs; 1999 Feb; 57(2):215-21; discussion 222-3. PubMed ID: 10188762
[TBL] [Abstract][Full Text] [Related]
10. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
[TBL] [Abstract][Full Text] [Related]
12. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
André P; Arbeille B; Drouet V; Hainaud P; Bal dit Sollier C; Caen JP; Drouet LO
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):56-63. PubMed ID: 8548427
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
14. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.
J Am Coll Cardiol; 1998 Dec; 32(7):2003-10. PubMed ID: 9857885
[TBL] [Abstract][Full Text] [Related]
15. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
16. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
17. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
18. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
[TBL] [Abstract][Full Text] [Related]
19. Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty.
Chico TJ; Chamberlain J; Gunn J; Arnold N; Bullens SL; Gadek TR; Francis SE; Bunting S; Horton M; Shepherd L; Lipari MT; Quan C; Knolle J; Stilz HU; Peyman A; Crossman DC
Circulation; 2001 Feb; 103(8):1135-41. PubMed ID: 11222478
[TBL] [Abstract][Full Text] [Related]
20. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee.
Moliterno DJ
Am Heart J; 2000 Apr; 139(4):563-6. PubMed ID: 10740135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
